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Background
Right ventricular (RV) failure is a major complication of
pulmonary arterial hypertension (PAH). Cardiovascular
magnetic resonance (CMR) can accurately quantify RV
volume and function. Short-term changes in CMR mea-
surements of RV size and function in PAH patients on
individualized therapy have not been extensively studied;
therefore, the required sample size for detecting a certain
change in RV size and function in response to therapy is
unknown. This study was designed to (1) assess changes
in RV size and function in patients on individualized PAH
treatment, and (2) to estimate sample sizes needed to
detect a change in RV function in future PAH drug trials
without discontinuing standard therapy.
Methods
Nineteen patients with category I PAH were prospectively
recruited. Patients were imaged using a 1.5-T scanner at
baseline and after 6 months. Retrospectively gated steady-
state free precession short axis cines were used to measure
RV end-diastolic volume index (RVEDVI) and ejection
fraction (EF) by Simpson’s method of disks. Both sets of
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Table 1 Baseline characteristics
Characteristic (N=19)
Age (years): average ±SD (range) % Female Body surface area(m2): average ±SD 52±11 (28-67) 95% 1.8±0.2
WHO functional class
I (%) II (%) III (%) Unknown (%) 32% 37% 26% 5%
Past medical history
None Hypothyroidism Atrial fibrillation Other (hypertension, stroke, asthma) 10 (53%) 6 (32%) 1 (5%) 5 (26%)
Etiology of pulmonary hypertension
Idiopathic Congenital Connective tissue disease/scleroderma Other (HIV, anorexigen use) 7 (37%) 4 (21%) 3 (16%) 5 (26%)
Therapy for pulmonary hypertension
No therapy Single-therapy Multi-therapy (2 or more agents) 2 (11%) 6 (32%) 11 (58%)
Baseline right ventricular size and function measurements (means)
RVEF (%) RVEDVI (ml/m2) RVESVI (ml/m2) 35±12 136±41 91±38
SD = standard deviation; WHO, World Health Organization; RVEF, right ventricular ejection fraction; RVEDVI, right ventricular end-diastolic volume index; RVESVI,
right ventricular end-systolic volume index
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CMR data were analyzed by 2 independent observers,
whose measurements were averaged. Paired, 2-sided t-
tests were performed to compare end-diastolic volumes
and EFs at baseline and follow up. Sample size calculations
to detect changes in RVEDVI and EF over time were per-
formed using Stata software.
Results
Clinical characteristics and baseline measurements are
shown in Table 1. Although after 6 months, 53% had an
increase in EF≥3% and 26% an increase in EF≥5%, in the
overall cohort, there was no significant difference over
time in either mean RVEDVI (ΔEDVI 3±17ml/m2, NS) or
mean RVEF (ΔEF 1±4%, NS) (Figure). To detect a 5% dif-
ference in ΔEF between a group of patients receiving stan-
dard + new treatment versus a group receiving standard
treatment + placebo (90% power, a=0.05), 22 patients in
each group would be required (or to detect a 3% differ-
ence, 59 patients per group). Detecting a 20ml/m2 change
in RVEDVI would require 16 patients per group (or 61
patients per group to detect a change of 10ml/m2).
Conclusions
CMR can be used to detect the effects of new PAH
therapies on RV volume and function with relatively
small groups of patients.
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